SBIO ETF
ALPS Medical Breakthroughs ETF
SBIO ETF Overview
SBIO ETF (ALPS Medical Breakthroughs ETF) is managed by ALPS Advisors with $220.6M in net assets. SBIO expense ratio is 0.50%, holding 107 positions across sectors including Health Care. Inception date: 2014-12-30.
SBIO performance shows a YTD return of 24.18%. The 1-year return is 94.10% and the 5-year return is 8.34%.
SBIO top holdings include Crinetics Pharmaceuticals Inc Com (4.7%), Apogee Therapeutics Inc (4.5%), Xenon Pharmaceuticals Inc. Common Shares (3.4%), Cg Oncology Inc (3.3%), Dianthus Therapeutics Inc (3.0%). Go to all SBIO holdings, SBIO sectors, or SBIO dividends.
SBIO can be compared against other funds. Use SBIO overlap to find shared positions, or SBIO vs another fund for a side-by-side view. SBIO alternatives are available via the screener, along with tax-loss harvesting opportunities.